Indication: Urothelial Carcinoma
A Phase Ib/II Open Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Locally Advanced Or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy (MORPHEUS-mUC)
Patients with locally advanced or metastatic
Sub-indication: Multiple immunotherapy-based treatment combinations in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma
Line of Therapy: 2nd or 3rd Line
Principal Investigator: Chandler Park, M.D.Norton Cancer Institute
Sponsor: F. Hoffmann-LaRoche Ltd.
Email for more information: GU-NCIResearch@nortonhealthcare.org